Additional information on the collaborative groups involved in the Taskforce
Lisa Butterfield, University of Pittsburgh
25 February 2009
The iSBTc has brought together experts from multiple stakeholders who have been focusing significant effort in this area including the United States Food and Drug Administration (FDA); the National Cancer Institute (NCI); the National Institutes of Health (NIH); members from industry; and partnering organizations such as the Biotherapy Development Association (BDA), Association for Immunotherapy of Cancer (CIMT), Cancer Vaccine Consortium (CVC), Nordic Center for Development of Antitumour Vaccines (NCV-network), the Italian Network for Tumor Biotherapy (NIBIT) as well as academic experts in the field of immunologic biomarker development and standardization. The planned October 2009 workshop is unique in that it is meant to be an interactive exchange rather than merely a didactic exercise, as it is organized around lively discussion and sharing of data on biomarker development. Ultimately, the workshop will define the “state of the art” in assay and cellular product development and standardization.
"iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", to take place October 28, 2009, Washington, D.C. Website: www.isbtc.org
Competing interests
no competing interests, other than paper co-author and workshop co-organizer.
Additional information on the collaborative groups involved in the Taskforce
25 February 2009
The iSBTc has brought together experts from multiple stakeholders who have been focusing significant effort in this area including the United States Food and Drug Administration (FDA); the National Cancer Institute (NCI); the National Institutes of Health (NIH); members from industry; and partnering organizations such as the Biotherapy Development Association (BDA), Association for Immunotherapy of Cancer (CIMT), Cancer Vaccine Consortium (CVC), Nordic Center for Development of Antitumour Vaccines (NCV-network), the Italian Network for Tumor Biotherapy (NIBIT) as well as academic experts in the field of immunologic biomarker development and standardization. The planned October 2009 workshop is unique in that it is meant to be an interactive exchange rather than merely a didactic exercise, as it is organized around lively discussion and sharing of data on biomarker development. Ultimately, the workshop will define the “state of the art” in assay and cellular product development and standardization.
"iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", to take place October 28, 2009, Washington, D.C.
Website: www.isbtc.org
Competing interests
no competing interests, other than paper co-author and workshop co-organizer.